Intracerebral Hemorrhage

An intracerebral hemorrhage happens when a blood vessel in the brain bursts and blood leaks throughout the brain.

Doctors + Care Team

David E. Thaler, MD, PhD, FAHA

David E. Thaler, MD, PhD, FAHA

Accepting New Patients

Virtual Appointments Available

Title(s): Neurologist-in-Chief; Chairman and Professor, Department of Neurology, Tufts University School of Medicine
Department(s): Neurology
Appt. Phone: 617-636-4948
Fax #: 617-636-8199

Stroke

View Full Profile for David E. Thaler, MD, PhD, FAHA

Adel M. Malek, MD, PhD

Adel M. Malek, MD, PhD

Accepting New Patients

Virtual Appointments Available

Title(s): Chief, Neurovascular Surgery; Director, Cerebrovascular & Endovascular Division Professor, Tufts University School of Medicine
Department(s): Neurosurgery
Appt. Phone: 617-636-8200
Fax #: 617-636-7587

Aneurysms, arteriovenous malformations, dural fistulas, subarachnoid hemorrhage, intracranial atherosclerosis, arterial dissection

View Full Profile for Adel M. Malek, MD, PhD

Joshua Kornbluth, MD

Joshua Kornbluth, MD

Title(s): Medical Director, Neurosciences Critical Care Unit; Program Director, Neurology Residency and Neurocritical Care Fellowship; Neurologist; Assistant Professor, Tufts University School of Medicine
Department(s): Neurology
Appt. Phone: 617-636-4948
Fax #: 617-636-8199

Neurocritical care

View Full Profile for Joshua Kornbluth, MD

Research + Clinical Trials


Statins Use in Intracerebral Hemorrhage Patients

SATURN is a multi-center, pragmatic, prospective, randomized, open-label, and blinded end-point assessment (PROBE) clinical trial. A total of 1,456 patients presenting within 7 days of a spontaneous lobar ICH while taking statins will be randomized to one of two treatment strategies: discontinuation vs. continuation of statin therapy (using the same agent and dose that they were using at ICH onset). Participating subjects will undergo baseline testing for APOE genotype and will be followed for 24 months to assess for the occurrence of recurrent symptomatic ICH or major adverse cerebro-/cardio-vascular events (MACCE) during the follow-up period
More information about research and clinical trials


Anticoagulation in ICH Survivors for Stroke Prevention and Recovery

ASPIRE is a randomized, double-blinded, phase III clinical trial designed to test the efficacy and safety of anticoagulation, compared with aspirin, in patients with a recent ICH and high-risk non-valvular AF (CHA2DS2-VASc score ≥ 2). Seven hundred patients will be enrolled over 3.5 years and followed for study outcomes for a minimum of 12 months and maximum of 36 months. The primary efficacy outcome is any stroke (hemorrhagic or ischemic) or death from any cause. The secondary efficacy outcome is the change in the modified Rankin Scale score. Recruitment will take place at sites coordinated through the NIH/NINDS StrokeNet.
More information about research and clinical trials


Statins Use In Intracerebral Hemorrhage Patients

SATURN is a multi-center, pragmatic, prospective, randomized, open-label, and blinded end-point assessment (PROBE) clinical trial. A total of 1,456 patients presenting within 7 days of a spontaneous lobar ICH while taking statins will be randomized to one of two treatment strategies: discontinuation vs. continuation of statin therapy (using the same agent and dose that they were using at ICH onset). Participating subjects will undergo baseline testing for APOE genotype and will be followed for 24 months to assess for the occurrence of recurrent symptomatic ICH or major adverse cerebro-/cardio-vascular events (MACCE) during the follow-up period.
More information about research and clinical trials